Clinical Trial Update: Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer. [EARLY_Phase 1]

View source ↗

Summary

An early-phase Phase 1 trial evaluating DC-CIK cell therapy combined with Epaloliposide, Vortexil, and Regorafenib as a third-line treatment for advanced colore…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• DC-CIK cell therapy
• Epaloliposide
• Regorafenib (regorafenib)
• Vortexil

Snippet

Sponsor: JIANG LONGWEI | Conditions: DC-CIK Treatment, Regorafenib | EARLY_Phase 1 | Status: RECRUITING